Letter in response to the LEADR ICD lead study: Is thinner better?

J Cardiovasc Electrophysiol

Department of Internal Medicine, Division of Cardiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Published: February 2023

Download full-text PDF

Source
http://dx.doi.org/10.1111/jce.15786DOI Listing

Publication Analysis

Top Keywords

letter response
4
response leadr
4
leadr icd
4
icd lead
4
lead study
4
study thinner
4
thinner better?
4
letter
1
leadr
1
icd
1

Similar Publications

Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficacy of CAR therapy. However, the effect of different bridging strategies on outcome, side effects and response to CAR therapy is still poorly understood.

View Article and Find Full Text PDF

Zellweger spectrum disorder presenting with opsoclonus-myoclonus-ataxia syndrome: a case report on immunotherapy.

Acta Neurol Belg

January 2025

Department of Pediatrics, Neurology Unit, University of Health Sciences, Ankara Etlik City Hospital, Ankara, Turkey.

Introduction: Zellweger spectrum disorder (ZSD) refers to a group of autosomal recessive genetic disorders that affect multiple organ systems and are predominantly caused by pathogenic variants in PEX genes. ZSD present a wide clinical spectrum, ranging from the most severe form, Zellweger syndrome, to the mildest form, Heimler syndrome.

Case Report: A 14-month-old male patient was brought to our clinic with recent-onset ocular tremors and unsteady gait.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!